Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board

Dec 07, 2015, 11:18 ET from Applied BioMath

WINCHESTER, Mass., Dec. 7, 2015 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com) is thrilled to announce that Dr. Joseph Loscalzo, MD, PhD is the newest member if its Scientific Advisory Board. Dr. Loscalzo is chair of the Department of Medicine and physician-in-chief at Brigham and Women's Hospital (BWH). A cardiovascular medicine specialist, he is also the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School (HMS). 

Dr. Loscalzo's clinical and research interests include vascular biology, thrombosis, atherosclerosis and systems biology. His most recent work has established the field of network medicine, a discipline that seeks to redefine disease and therapeutics from an integrated perspective using systems biology and network science. He has received research support from the National Institutes of Health, authored over 500 peer-reviewed articles and holds 31 patents for his work in the field of nitric oxide and redox biology.

As a member of Applied BioMath's distinguished Scientific Advisory Board, Dr. Loscalzo will advise and consult on current and future projects. He joins a board comprised of pioneers and thought leaders in the mathematical modeling, biological engineering, and medical fields, including key opinion leaders Douglas Lauffenburger, PhD, Bruce Tidor, PhD, and Michael Yaffe, MD, PhD. 

"Applied BioMath prides its self on taking the biology and medical aspects of projects just as seriously at the modeling and simulation. Joe Loscalzo brings world class clinical and biological expertise to our Science Advisory Board and will help continue to push ABM to be a leader in Systems Pharmacology."

Dr. Joshua Apgar, PhD, Co-Founder and CSO, Applied BioMath

About Applied BioMath

Applied BioMath (www.appliedbiomath.com), helps biotech and pharmaceutical companies reduce late stage attrition and accelerate best-in-class (BIC) drugs using quantitative methodologies. Leveraging biology, high performance computing (HPC), proprietary technology and experience in pharma, Applied BioMath delivers biological insights proven to shorten project timelines, lower costs, and develop BIC drugs. Services include knowledge gap analysis, experiment prioritization and design, BIC drug property and tox predictions, indication and patient selection, and optimal clinical trial design and analysis.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella

Photo - http://photos.prnewswire.com/prnh/20151207/293672
Logo - http://photos.prnewswire.com/prnh/20150915/266672LOGO

SOURCE Applied BioMath